Sanofi

Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Medical Marketing and Media
Sanofi
Regeneron
Dupixent
clinical trials
COPD
Flag link:
With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma's patent tactics
With filing in Sanofi and Mylan insulin lawsuit, FTC amps up scrutiny on pharma's patent tactics
Fierce Pharma
Sanofi
Mylan
legal
FTC
insulin
diabetes
Flag link:
Senate Democrats press Sanofi and AZ for answers as 'unprecedented' demand spurs shortage of RSV antibody Beyfortus
Senate Democrats press Sanofi and AZ for answers as 'unprecedented' demand spurs shortage of RSV antibody Beyfortus
Fierce Pharma
Sanofi
AstraZeneca
Senate
CDC
RSV
Beyfortus
drug shortages
Flag link:
Can This Pharma CEO Change The Way Drugs Are Discovered, Developed, And Delivered With AI?
Can This Pharma CEO Change The Way Drugs Are Discovered, Developed, And Delivered With AI?
Forbes
Sanofi
Paul Hudson
R&D
Pharma CEOs
Flag link:
Sanofi pays $30M for first look at MeiraGTx's data and a shot to brew up deals
Sanofi pays $30M for first look at MeiraGTx's data and a shot to brew up deals
Fierce Biotech
Sanofi
MeiraGTx
riboswitch
drug development
Flag link:
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
earnings
Bristol Myers Squibb
Takeda
Novartis
Sanofi
Merck
Flag link:
Sanofi loses $21 bln in market value after dropping 2025 profit target
Sanofi loses $21 bln in market value after dropping 2025 profit target
Reuters
Sanofi
earnings
spinoffs
consumer health
Flag link:
Sanofi loses $21 bln in market value after dropping 2025 profit target
Sanofi loses $21 bln in market value after dropping 2025 profit target
Reuters
Sanofi
Paul Hudson
Pharma CEOs
Flag link:
Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts
Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts
Fierce Biotech
Sanofi
Denali
Kymab
Principia Biopharma
Flag link:
Sanofi reports positive data from Phase III trial of Dupixent
Sanofi reports positive data from Phase III trial of Dupixent
Clinical Trials Arena
Sanofi
clinical trials
Dupixent
eosinophilic esophagitis
pediatric
Flag link:
Dupixent returns as top Rx, OTC brand for September
Dupixent returns as top Rx, OTC brand for September
Medical Marketing and Media
Sanofi
Regeneron
Dupixent
DTC ads
pharma ads
Flag link:
BioMap Establishes a Strategic Collaboration with Sanofi to Co-Develop AI Modules to Accelerate Drug Discovery for Biotherapeutics
BioMap Establishes a Strategic Collaboration with Sanofi to Co-Develop AI Modules to Accelerate Drug Discovery for Biotherapeutics
BioSpace
Sanofi
BioMap
artificial intelligence
Flag link:
Sanofi spin-off EuroAPI slumps as revenues falter
Sanofi spin-off EuroAPI slumps as revenues falter
Pharmaphorum
Sanofi
EuroAPI
spinoffs
API
Flag link:
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Fierce Pharma
Mirati Therapeutics
Sanofi
M&A
KRAS inhibitors
Flag link:
Sanofi pays Teva $500M to join Merck, Roivant in red-hot bowel disease race
Sanofi pays Teva $500M to join Merck, Roivant in red-hot bowel disease race
Fierce Biotech
Sanofi
Teva Pharmaceutical
inflammatory bowl disease
IBD
Merck
Roivant
Flag link:
Sanofi pays J&J $175M for late-phase E. coli shot, pushing deeper into vaccines as partner retreats
Sanofi pays J&J $175M for late-phase E. coli shot, pushing deeper into vaccines as partner retreats
Fierce Biotech
Sanofi
JNJ
vaccines
E. coli
Flag link:
Sanofi Sells 11 CNS Assets to Pharmanovia including Frisium and Gardenal
Sanofi Sells 11 CNS Assets to Pharmanovia including Frisium and Gardenal
BioSpace
Sanofi
Pharmanovia
CNS
Frisium
Gardenal
Flag link:
Sanofi Consumer Healthcare’s Road To Sustainability And B Corp Certification
Sanofi Consumer Healthcare’s Road To Sustainability And B Corp Certification
Forbes
Sanofi
consumer health
sustainability
Flag link:
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Fierce Biotech
Madrigal Pharmaceuticals
Pharma CEOs
Sanofi
Bill Sibold
NASH
Flag link:
Sanofi appoints a venture investor to R&D head as executive team expands
Sanofi appoints a venture investor to R&D head as executive team expands
BioPharma Dive
Sanofi
R&D
Houman Ashrafian
Flag link:

Pages